Biodexa Pharmaceuticals (BDRX)
4.21
-0.09 (-2.09%)
At close: Jan 14, 2025, 3:58 PM
4.20
-0.24%
After-hours Jan 14, 2025, 06:27 PM EST
undefined% (undefined)
| Bid | 3.8 |
| Market Cap | 978.13M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -73.22 |
| PE Ratio (ttm) | -0.06 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 5.5 |
| Volume | 5,734 |
| Avg. Volume (20D) | 289,236 |
| Open | 4.32 |
| Previous Close | 4.30 |
| Day's Range | 4.13 - 4.32 |
| 52-Week Range | 3.50 - 74.00 |
| Beta | undefined |
About BDRX
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 7, 2015
Employees 21
Stock Exchange NASDAQ
Ticker Symbol BDRX
Website https://www.biodexapharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for BDRX stock is "Buy." The 12-month stock price forecast is $200, which is an increase of 4650.59% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago ·
Source
-30.12%
Bioedexa Pharmaceuticals shares are trading lower....
Unlock content with
Pro Subscription
3 months ago ·
Source
+67.66%
Biodexa Pharmaceuticals shares are trading higher after the company announced it successfully appealed Nasdaq's delisting decision and was granted a time extension to demonstrate compliance with its listing rule.
